105 related articles for article (PubMed ID: 36204872)
1. Intratumoral heterogeneity contributes to the chemotherapy prognosis of breast cancer.
Li Y; Wang M; Yang S; Kuang L; Tao X; Yang J; Zhao W; Zhang J
J Cancer Res Ther; 2022 Sep; 18(5):1268-1275. PubMed ID: 36204872
[TBL] [Abstract][Full Text] [Related]
2. Intra-tumoral heterogeneity and immune responses predicts prognosis of gastric cancer.
Feng W; Wang Y; Chen S; Zhu X
Aging (Albany NY); 2020 Nov; 12(23):24333-24344. PubMed ID: 33259333
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.
Ma D; Jiang YZ; Liu XY; Liu YR; Shao ZM
Breast Cancer Res Treat; 2017 Feb; 162(1):39-48. PubMed ID: 28093659
[TBL] [Abstract][Full Text] [Related]
4. Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma.
Mroz EA; Patel KB; Rocco JW
Cancer; 2020 Jan; 126(9):1895-1904. PubMed ID: 32083741
[TBL] [Abstract][Full Text] [Related]
5. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
6. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
Sui S; An X; Xu C; Li Z; Hua Y; Huang G; Sui S; Long Q; Sui Y; Xiong Y; Ntim M; Guo W; Chen M; Deng W; Xiao X; Li M
Theranostics; 2020; 10(26):11938-11949. PubMed ID: 33204321
[No Abstract] [Full Text] [Related]
7. Clinical relevance of mutant-allele tumor heterogeneity and lung adenocarcinoma.
Mao H
Ann Transl Med; 2019 Sep; 7(18):432. PubMed ID: 31700868
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
10. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas.
Mroz EA; Tward AD; Hammon RJ; Ren Y; Rocco JW
PLoS Med; 2015 Feb; 12(2):e1001786. PubMed ID: 25668320
[TBL] [Abstract][Full Text] [Related]
11. Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis.
Han Y; Liu X; Ye H; Tian Y; Ji Z
World J Surg Oncol; 2020 Nov; 18(1):310. PubMed ID: 33243261
[TBL] [Abstract][Full Text] [Related]
12. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
Hou Y; Nitta H; Wei L; Banks PM; Portier B; Parwani AV; Li Z
Breast Cancer Res Treat; 2017 Nov; 166(2):447-457. PubMed ID: 28799059
[TBL] [Abstract][Full Text] [Related]
13. PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy.
Fan Y; Xie G; Wang Z; Wang Y; Wang Y; Zheng H; Zhong X
Breast Cancer Res Treat; 2022 Feb; 192(1):33-42. PubMed ID: 34978016
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of mutant-allele tumor heterogeneity in uterine corpus endometrial carcinoma.
Hou Y; Li T; Gan W; Lv S; Zeng Z; Yan Z; Wang W; Yang M
Ann Transl Med; 2020 Mar; 8(6):339. PubMed ID: 32355783
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
Gagliato Dde M; Gonzalez-Angulo AM; Lei X; Theriault RL; Giordano SH; Valero V; Hortobagyi GN; Chavez-Macgregor M
J Clin Oncol; 2014 Mar; 32(8):735-44. PubMed ID: 24470007
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic significance of CD8
Al-Saleh K; Abd El-Aziz N; Ali A; Abozeed W; Abd El-Warith A; Ibraheem A; Ansari J; Al-Rikabi A; Husain S; Nabholtz JM
Oncol Lett; 2017 Jul; 14(1):337-344. PubMed ID: 28693173
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
18. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Toomey S; Madden SF; Furney SJ; Fan Y; McCormack M; Stapleton C; Cremona M; Cavalleri GL; Milewska M; Elster N; Carr A; Fay J; Kay EW; Kennedy S; Crown J; Gallagher WM; Hennessy BT; Eustace AJ
Oncotarget; 2016 Nov; 7(46):75518-75525. PubMed ID: 27776352
[TBL] [Abstract][Full Text] [Related]
19. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study.
Yoo SH; Kang SY; Cheon GJ; Oh DY; Bang YJ
J Nucl Med; 2020 Jan; 61(1):33-39. PubMed ID: 31201247
[TBL] [Abstract][Full Text] [Related]
20. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
Shen K; Yao L; Zhu J; Gu X; Wang J; Qian W; Zheng Z; Fu D; Wu S
BMC Cancer; 2022 Aug; 22(1):863. PubMed ID: 35941565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
